SCHEMBL24726522

SCHEMBL24726522

CC(C)c1cccc(-c2ccc(C#N)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.54
RXRB P28702 1/20 0.54
RXRG P48443 1/20 0.54
PSEN1 P49768 2/20 0.48
PSEN2 P49810 2/20 0.48
APH1B Q8WW43 2/20 0.48
NCSTN Q92542 2/20 0.48
APH1A Q96BI3 2/20 0.48
PSENEN Q9NZ42 2/20 0.48
PTPN5 P54829 2/20 0.47
CTSS P25774 2/20 0.46
CTSK P43235 2/20 0.46
CYP11B2 P19099 1/20 0.43
KIF11 P52732 3/20 0.43
MMP3 P08254 1/20 0.42
HSD11B1 P28845 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23625544 0.89 CYP11B2 (0.43) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL8240673 0.87 CLK4 (0.49) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL24017151 0.83 KIF11 (0.47) CYP11B2KIF11MMP3HSD11B1GRIA1
SCHEMBL598181 0.82 RXRA (0.66) RXRARXRBRXRGPTPN5CTSS
SCHEMBL12919972 0.82 ADAMTS4 (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL24617563 0.81 HRH3 (0.50) CYP11B2KIF11MMP3GRIA1GRIA2
SCHEMBL29727265 0.81 RXRA (0.65) RXRARXRBRXRGPTPN5KIF11
SCHEMBL5355878 0.81 RXRA (0.65) RXRARXRBRXRGPTPN5KIF11
SCHEMBL12263202 0.81 MMP3 (0.52) CYP11B2KIF11MMP3GRIA1GRIA2
SCHEMBL22507033 0.80 MMP3 (0.56) PTPN5CYP11B2KIF11MMP3GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 US disclosed
US-11723271-B2 Organic compound, and electronic component and electronic device therefor SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-08-08 US disclosed
US-20230200234-A1 ORGANIC COMPOUND, AND ELECTRONIC COMPONENT AND ELECTRONIC DEVICE THEREFOR SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-06-22 US disclosed
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-01-19 US disclosed
WO-2022234965-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 보로노이 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230200234-A1 ORGANIC COMPOUND, AND ELECTRONIC COMPONENT AND ELECTRONIC DEVICE THEREFOR OR51E2, CYP4F11, OR10J3 RXRA 1737/4885RXRB 1738/4885RXRG 2356/4885
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 RXRA 928/4885RXRB 798/4885RXRG 845/4885
US-11723271-B2 Organic compound, and electronic component and electronic device therefor OR51E2, CYP4F11, OR10J3 RXRA 1737/4885RXRB 1738/4885RXRG 2356/4885
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 RXRA 928/4885RXRB 798/4885RXRG 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.